Wed, Oct 1, 2014 15:18
HomeMost Recent NewsLone Star Business BlogContact Us
Advertise with Texas Business
IDEV Technologies Names Trent Reutiman As Vice President, Global Commercial Operations

Texas Business reports: WEBSTER, Texas—IDEV Technologies Inc. a provider of peripheral vascular devices, hired Trent Reutiman as vice president, global commercial operations. 

He joins the company after successful sales and marketing positions at ROX Medical and several other start-ups.  His early career was in sales and sales management at Guidant and Cordis.

In addition to Reutiman, IDEV has further supplemented the global team with additional hires in key areas including the commercial organization, product development, and operations as the company continues to develop its business through organic growth, new product launches, and geographic expansion.

“The addition of Trent to our senior management team is a reflection of our commitment to further expand our capabilities, and to execute our long term strategy,” said IDEV chief executive Christopher Owens in a prepared statement. “All the new resources bring global experience that further enhances our existing organization as we work to develop and complement our unique technology platform.”

Reutiman, in this newly created role, will lead the global sales and marketing teams as the company continues to expand distribution and sales of its flagship product, the Supera stent.

“I’m excited to join IDEV at this time,” said Reutiman in a statement. “With recent product launches in multiple countries in the Asia Pacific region, continued market penetration in Europe, and intense preparations for the anticipated FDA approval of the SUPERA stent in the U.S., we are setting strategies that are vital to successful commercial execution.”

IDEV Technologies Incorporated (IDEV) develops medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.

The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in multiple other countries for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).